Gilead Sciences 3rd Quarter Financial Results

From Gilead Sciences 
Gilead Sciences (GILD) Chairman and CEO Daniel O’Day, said, “Gilead’s third-quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this strong topline growth and disciplined operating expense management . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.